Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Mo : vimarsana.com

- Phosphorylation-inducing chimeric small molecules (PHICS) are a new class of bifunctional medicines that direct and repair aberrant and dysfunctional proteins- PHICS enable precise phosphorylation, an important post-translational modification that controls protein function, including activation, stabilization, tra...

Related Keywords

Berkeley , California , United States , Salk Institute , Dan Nomura , Wendy Young , Renato Dulbecco , Eli Lilly , Tony Hunter , Brian Fenton , Angela Koehler , Briggs Morrison , Amit Choudhary , David Steinberg , Otello Stampacchia , Eric Fischer , Edward Holson , Luke Evnin , Arkin Bio , Lizzie Ngo , University Of California , Broad Institute , Koch Institute , Syndax Pharmaceuticals , Swanson Biotechnology Center High , Merck Co , University Of Massachusetts , Worcester Polytechnic Institute , Cancer Research , Atlas Venture , Nutritional Sciences , University Of Virginia , Partner At Longwood Fund , Department Of Pharmaceutical Chemistry , Ventures Fund , Longwood Fund Principal , Longwood Fund , Investigator At Dana Farber Cancer Institute , Photys Therapeutics , Omega Funds , Mass General Brigham Ventures , Heritage Medical , Chief Scientific Officer , Chief Executive , General Partner , Managing Director , Alon Lazarus , Investment Manager , Executive Partner , Amathus Therapeutics , Chief Business Officer , Translate Bio , Rare Disease Business Development Group , Chemical Engineering , Worcester Polytechnic , Photys Scientific Advisory Board , Independent Investigator , Dana Farber Cancer Institute , Renato Dulbecco Chair , Associate Professor , Biological Engineering , Institute Fellow , Chemical Biology , Cell Biology , Adjunct Professor , Pharmaceutical Chemistry , Phosphorylation Inducing Chimeric Small Molecules ,